Validation of a Diagnostic Model to Differentiate Multiple Myeloma from Bone Metastasis

References

• Weber KL. Evaluation of the adult patient (aged >40 years) with a destructive bone lesion. J Am Acad Orthop Surg. 2010;18(3):169–179. doi:10.5435/00124635-201003000-00006
   PubMed Web of Science ®Google Scholar
• Utzschneider S, Schmidt H, Weber P, Schmidt GP, Jansson V, Dürr HR. Surgical therapy of skeletal complications in multiple myeloma. Int Orthop. 2011;35(8):1209–1213. doi:10.1007/s00264-010-1127-0
   PubMed Web of Science ®Google Scholar
• Baykara M, Yildirim M. Differentiation of multiple myeloma and metastases with apparent diffusion coefficient map histogram analysis. North Clin Istanb. 2022;9(3):256–260.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Jee WH, Ha KY, et al. MR distinction between multiple myeloma and metastasis involving the spine. J Korean Radiol Soc. 2016;44(2):229–235. doi:10.3348/jkrs.2001.44.2.229
   Google Scholar
• Kim HJ, Ryu KN, Choi WS, Choi BK, Choi JM, Yoon Y. Spinal involvement of hematopoietic malignancies and metastasis: differentiation using MR imaging. Clin Imaging. 1999;23(2):125–133. doi:10.1016/S0899-7071(99)00105-9
   PubMed Web of Science ®Google Scholar
• Kariyawasan CC, Hughes DA, Jayatillake MM, Mehta AB. Multiple myeloma: causes and consequences of delay in diagnosis. QJM. 2007;100(10):635–640. doi:10.1093/qjmed/hcm077
   PubMed Web of Science ®Google Scholar
• Koshiaris C. Methods for reducing delays in the diagnosis of multiple myeloma. Int J Hematol Oncol. 2019;8(1):IJH13. doi:10.2217/ijh-2018-0014
   PubMedGoogle Scholar
• Ryan C, Stoltzfus KC, Horn S, et al. Epidemiology of bone metastases. Bone. 2022;158:115783. doi:10.1016/j.bone.2020.115783
   PubMed Web of Science ®Google Scholar
• Zhou L, Yu Q, Wei G, et al. Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer. 2021;21(1):606. doi:10.1186/s12885-021-08280-y
   PubMed Web of Science ®Google Scholar
• Phinyo P, Maihom T, Phanphaisarn A, et al. Development of a clinical diagnostic tool to differentiate multiple myeloma from bone metastasis in patients with destructive bone lesions (MM-BM DDx). BMC Fam Pract. 2020;21(1):215.
   PubMed Web of Science ®Google Scholar
• Phinyo P, Maihom T, Phanphaisarn A, et al. Correction: development of a clinical diagnostic tool to differentiate multiple myeloma from bone metastasis in patients with destructive bone lesions (MM-BM DDx). BMC Prim Care. 2022;23(1):189. doi:10.1186/s12875-022-01785-w
   PubMedGoogle Scholar
• Debray TPA, Vergouwe Y, Koffijberg H, Nieboer D, Steyerberg EW, Moons KGM. A new framework to enhance the interpretation of external validation studies of clinical prediction models. J Clin Epidemiol. 2015;68(3):279–289. doi:10.1016/j.jclinepi.2014.06.018
   PubMed Web of Science ®Google Scholar
• World Medical Association. World Medical Association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. doi:10.1001/jama.2013.281053
   PubMed Web of Science ®Google Scholar
• Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement. BMC Med. 2015;13(1):1. doi:10.1186/s12916-014-0241-z
   PubMedGoogle Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–548. doi:10.1016/S1470-2045(14)70442-5
   PubMed Web of Science ®Google Scholar
• Riley RD, Debray TPA, Collins GS, et al. Minimum sample size for external validation of a clinical prediction model with a binary outcome. Stat Med. 2021;40(19):4230–4251. doi:10.1002/sim.9025
   PubMed Web of Science ®Google Scholar
• Morris TP, White IR, Royston P. Tuning multiple imputation by predictive mean matching and local residual draws. BMC Med Res Methodol. 2014;14(1):75. doi:10.1186/1471-2288-14-75
   PubMedGoogle Scholar
• Marshall A, Altman DG, Holder RL, Royston P. Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med Res Methodol. 2009;9:57. doi:10.1186/1471-2288-9-57
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420. doi:10.1200/JCO.2005.04.242
   PubMed Web of Science ®Google Scholar
• Vergouwe Y, Moons KGM, Steyerberg EW. External validity of risk models: use of benchmark values to disentangle a case-mix effect from incorrect coefficients. Am J Epidemiol. 2010;172(8):971–980. doi:10.1093/aje/kwq223
   PubMed Web of Science ®Google Scholar
• Xiong X, Wang J, Hu S, Dai Y, Zhang Y, Hu C. Differentiating between multiple myeloma and metastasis subtypes of lumbar vertebra lesions using machine learning–based radiomics. Front Oncol. 2021;11:1.
   Web of Science ®Google Scholar
• Park GE, Jee WH, Lee SY, et al. Differentiation of multiple myeloma and metastases: use of axial diffusion-weighted MR imaging in addition to standard MR imaging at 3T. PLoS One. 2018;13(12):e0208860. doi:10.1371/journal.pone.0208860
   PubMed Web of Science ®Google Scholar
• McGee S. Simplifying likelihood ratios. J Gen Intern Med. 2002;17(8):647–650.
   Web of Science ®Google Scholar
• Eleutherakis-Papaiakovou V, Bamias A, Gika D, et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma. 2007;48(2):337–341. doi:10.1080/10428190601126602
   PubMed Web of Science ®Google Scholar
• Clark AD, Shetty A, Soutar R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev. 1999;13(2):79–90. doi:10.1016/S0268-960X(99)90014-0
   PubMed Web of Science ®Google Scholar
• Park S, Han B, Kim K, et al. Renal insufficiency in newly-diagnosed multiple myeloma: analysis according to International Myeloma Working Group consensus statement. Anticancer Res. 2014;34(8):4299–4306.
   PubMed Web of Science ®Google Scholar
• Cai Y, Zhao Y, Dai Q, Xu M, Xu X, Xia W. Prognostic value of the albumin–globulin ratio and albumin–globulin score in patients with multiple myeloma. J Int Med Res. 2021;49(3):0300060521997736. doi:10.1177/0300060521997736
   PubMed Web of Science ®Google Scholar
• Laudin GE, Levay PF, Coetzer B. Globulin fraction and albumin: globulin ratio as a predictor of mortality in a South African multiple myeloma cohort. Int J Hematol Oncol. 2020;9(3):IJH27. doi:10.2217/ijh-2020-0003
   PubMedGoogle Scholar
• Thio QCBS, Karhade AV, Notman E, et al. Serum alkaline phosphatase is a prognostic marker in bone metastatic disease of the extremity. J Orthop. 2020;22:346–351. doi:10.1016/j.jor.2020.08.008
   PubMed Web of Science ®Google Scholar
• Karhade AV, Thio QCBS, Kuverji M, Ogink PT, Ferrone ML, Schwab JH. Prognostic value of serum alkaline phosphatase in spinal metastatic disease. Br J Cancer. 2019;120(6):640–646. doi:10.1038/s41416-019-0407-8
   PubMed Web of Science ®Google Scholar
• Koshiaris C, Bruel den AV, Nicholson BD, Lay-Flurrie S, Hobbs FR, Oke JL. Clinical prediction tools to identify patients at highest risk of myeloma in primary care: a retrospective open cohort study. Br J Gen Pract. 2021;71(706):e347–55. doi:10.3399/BJGP.2020.0697
   PubMed Web of Science ®Google Scholar
• Smith L, Carmichael J, Cook G, Shinkins B, Neal RD. Development and internal validation of a risk prediction model to identify myeloma based on routine blood tests: a case-control study. Cancers. 2023;15(3):975.
   PubMed Web of Science ®Google Scholar
• Annibali O, Petrucci MT, Santini D, et al. Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: is there any difference? J Bone Oncol. 2020;26:100338. doi:10.1016/j.jbo.2020.100338
   PubMed Web of Science ®Google Scholar
• Altman RL, Lin CT, Earnest M. Problem-oriented documentation: design and widespread adoption of a novel toolkit in a commercial electronic health record. JAMIA Open. 2023;6(1):ooad005. doi:10.1093/jamiaopen/ooad005
   PubMedGoogle Scholar
• Jehn CF, Diel IJ, Overkamp F, et al. Management of metastatic bone disease algorithms for diagnostics and treatment. Anticancer Res. 2016;36(6):2631–2637.
   PubMed Web of Science ®Google Scholar
• Seesaghur A, Petruski-Ivleva N, Banks VL, et al. Clinical features and diagnosis of multiple myeloma: a population-based cohort study in primary care. BMJ Open. 2021;11(10):e052759. doi:10.1136/bmjopen-2021-052759
   PubMed Web of Science ®Google Scholar
• Mateos MV, Fink L, Koneswaran N, et al. Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review. BMC Cancer. 2020;20(1):170. doi:10.1186/s12885-020-6596-y
   PubMed Web of Science ®Google Scholar